EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ZYUS Life Sciences's Enterprise Value is C$76.22 Mil.
ZYUS Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was C$-18.29 Mil. Therefore, ZYUS Life Sciences's EV-to-FCF for today is -4.17.
The historical rank and industry rank for ZYUS Life Sciences's EV-to-FCF or its related term are showing as below:
TSXV:ZYUS'
s EV-to-FCF Range Over the Past 10 Years
Min: -17.73 Med: -4.05 Max: -3.32
Current: -4.28
During the past 3 years, the highest EV-to-FCF of ZYUS Life Sciences was -3.32. The lowest was -17.73. And the median was -4.05.
TSXV:ZYUS's EV-to-FCF is ranked worse than 100% of 525
companies
in the Drug Manufacturers industry
Industry Median: 24.52
vs TSXV:ZYUS: -4.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for ZYUS Life Sciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ZYUS Life Sciences's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's EV-to-FCF falls into.
ZYUS Life Sciences's current Enterprise Value is C$76.22 Mil.
ZYUS Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-18.29 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYUS Life Sciences (TSXV:ZYUS) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ZYUS Life Sciences's PE Ratio for today is calculated as:
ZYUS Life Sciences's share price for today is C$1.02.
ZYUS Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.817.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ZYUS Life Sciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of ZYUS Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
ZYUS Life Sciences (TSXV:ZYUS) Business Description
ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSXV:ZYUS has been successfully added to your 